Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


The importance of renin-angiotensin-aldosterone system in pathogenesis of different clinical conditions is studied well. The key role of aldosterone receptor blockers, particularly spironolactone, in treatment of such conditions as primary hyperaldosteronism, resistant hypertension, edematous syndrome in congestive heart failure, nephrotic syndrome, and portal cirrhosis is considered in the article. Development of ideas about cardio-, vaso- and nephroprotective effects of these drugs is highlighted as well as their influence on patient prognosis.

About the Authors

V. I. Podzolkov
Sechenov First Moscow State Medical University
Russian Federation

Valery I. Podzolkov - MD, PhD, Professor, Head of Chair of Faculty Therapy N2, Director of the University Clinic №4

N. A. Dragomiretskaya
Sechenov First Moscow State Medical University
Russian Federation
Natalya A. Dragomiretskaya - MD, PhD, Assistant Professor, Chair of Faculty Therapy N2


1. DеGennes L, Deltour G. Aldosterone, a new adrenocortical steroid. Presse Med. 1954;62(85): 1751-2.

2. Iudaev N.A. New steroid hormone of the adrenal cortex aldosterone (electrocortin)]. Problemy Endokrinologii i Gormonoterapii. 1955;1(1):118-20. (In Russ.) [Юдаев Н.А. Новый стероидный гормон коры надпочечников альдостерон (электрокортин). Проблемы Эндокринологии и Гормонотерапии. 1955;1(1):118-20].

3. Kagawa C.M., Van Arman C.G. Effects of cortisone and hydrocortisone on sodium excretion in adrenalectomized rats. Proc Soc Exp Biol Med. 1957;94(4):683-6.

4. Kagawa C.M., Sturtevant F.M., Van Arman C.G. Pharmacology of a new steroid that blocks salt activity of aldosterone and desoxycorticosterone. J Pharmacol Exp Ther. 1959;126(2):123-30.

5. Bolte E., Verdy M., Marc-Aureleet J. et al. Studies on New Diuretic Compounds: Spirolactone and Chlorothiazide. Can Med Assoc J. 1958;79(11):881–8.

6. Weber K.T., Brilla C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensinaldosterone system. Circulation. 1991;83(6):1849-65.

7. Giljarevskij S.R., Golshmid M.V., Kuz'mina I.M. The role of aldosterone-receptor antagonists in prevention and treatment of heart and kidney disease: actuality and promises. Russkiy Meditsinskiy Zhurnal.

8. ;23:1689-98. (In Russ.) [Гиляревский С.Р., Голшмид М.В., Кузьмина И.М. Роль антагонистов рецепторов альдостерона в профилактике и лечении сердечно-сосудистых и почечных заболеваний: реальность и перспективы. Русский Медицинский Журнал. 2014;23:1689-98].

9. Sabbadin C., Calo L.A., Armanini D. The story of spironolactones from 1957 to now: from sodium balance to inflammation. G Ital Nefrol. 2016;33Suppl 66:33.

10. Sica D.A. Spironolactone: an old friend rediscovered. J Clin Hypertens (Greenwich). 2006;8(7):467-9.

11. Funder J.W. Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr Blood Press Control. 2013;6:129-38.

12. Funder J.W. Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects. Endocrinol. 2006;147:5564-7.

13. Zannad F. Aldosterone and heart failure. Eur Heart J. 1995;16 Suppl N:98-102.

14. Ramires F.J., Mansur A., Coelho O. et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol. 2000;85(10):1207-11.

15. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429-35.

16. Mareev V.Ju. Guidelines for the rational management of heart failure. Consilium Medicum. 1999;3:13842. (In Russ.) [Мареев В.Ю. Рекомендации по рациональному лечению больных с сердечной недостаточностью. Consilium Medicum.1999;3:138-42].

17. Zannad F., Alla F., Dousset B. et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES) Rales Investigators. Circulation. 2000;102:2700-6.

18. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-17.

19. Vizzardi E., Nodari S., Caretta G., et al. Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms. The American Journal of the Medical Sciences. 2014;347(4):271-6.

20. Muldowney J.A. 3rd, Schoenhard J.A., Benge C.D. The clinical pharmacology of eplerenone. Expert Opin Drug Metab Toxicol. 2009;5(4):425-32.

21. Pitt B., Williams G., Remme W. et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther. 2001;15(1):79-87.

22. Zannad F., McMurray J.J., Krum H. et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364(1):11-21.

23. Podzolkov V.I., Rodionov A.V. Primary hyperaldosteronism: diagnosis and treatment. Arterialnaya Hypertenziya. 2004;10(2):109-14. (In Russ.) [Подзолков В.И., Родионов А.В. Первичный гиперальдостеронизм: диагностика и лечение. Артериальная Гипертензия. 2004;10(2):109-14].

24. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31(10):1925-38.

25. Parthasarathy K.H., Menard J., White W.B. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29:980-90.

26. Williams B., MacDonald T.M., Morant S. et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059-68.

27. Adams M., Bellone J.M., Wright B.M., et al. Evaluation and pharmacologic approach to patients with resistant hypertension. Postgrad Med. 2012;124(1):74-82.

28. Oliveras A., Armario P., ClaraA., et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial. J Hypertens. 2016;34(9):1863-71.

29. Biecker E. Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol. 2011;17(10): 1237-48.

30. Verma D., Thompson J., Swaminathan S. Spironolactone blocks Epstein-Barr virus production by inhibiting EBV SM protein function. Proc Natl Acad Sci USA. 2016;113(13):3609-14.

31. Dinh Q.N., Young M.J., Evans M.A., et al. Aldosterone-induced oxidative stress and inflammation in the brain are mediated by the endothelial cell mineralocorticoid receptor. Brain Res. 2016;1637: 146-53.

32. Bender S.B., DeMarco V.G., Padilla J., et al. Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction. Hypertension. 2015;65(5):1082-8.

33. Esposito C.T., Varahan S., Jeyaraj all. Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation. J Cardiovasc Electrophysiol. 2013; 24(7):806-12.

34. Вeygui F., Vicaut E., Ecollan P., et al. Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. Am Heart J. 2010;160:642-8

For citation:

Podzolkov V.I., Dragomiretskaya N.A. ALDOSTERONE ANTAGONISTS. MODERN VIEWS ON THE MECHANISM OF ACTION AND EFFECTS OF SPIRONOLACTONE. Rational Pharmacotherapy in Cardiology. 2017;13(2):263-269. (In Russ.)

Views: 1806

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)